ArticleThe Prostate2026
Impact of the Nadir Androgen Receptor Signaling Inhibitor-Derived Integrative Response Model in Real-World Patients With Metastatic Castration-Sensitive Prostate Cancer.
Article in The Prostate, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEarly deep prostate-specific antigen (PSA) decline after the initiation of androgen receptor signaling inhibitor (ARSI) therapy is associated with favorable long-term outcomes in metastatic castration-sensitive prostate cancer (mCSPC). The Nadir ARSI-Derived Integrative Response (NADIR) model was recently developed using Phase III trial data to predict the probability of achieving a favorable early PSA response. However, its performance in real-world clinical settings remains unclear.
methodsWe retrospectively reviewed 196 patients with mCSPC who received first-line ARSI therapy at Hiroshima University Hospital and affiliated institutions between 2018 and 2025; 186 had complete data required to calculate the NADIR score. An early favorable PSA response was defined as a decline in PSA to ≤ 0.2 ng/mL within 6 months of treatment initiation. Model discrimination was assessed using the area under the receiver operating characteristic curve (AUC), and calibration was evaluated using calibration plots. Patients were stratified into tertiles based on the NADIR score, and time-to-event outcomes, including overall survival (OS) and time to castration-resistant prostate cancer (CRPC), were analyzed using the Kaplan-Meier method.
resultsThe proportion of patients with an early favorable PSA response decreased stepwise across the upper, middle, and lower tertiles (61.3%, 33.8%, and 17.7%, respectively; Cochran-Armitage trend test, p < 0.01). The NADIR model demonstrated acceptable discrimination for predicting an early favorable PSA response, with an AUC of 0.74 (95% confidence interval [CI] 0.66-0.81). Agreement between predicted probabilities and observed outcomes was maintained across NADIR-defined risk groups. In a univariable analysis treating the NADIR score as a continuous variable, higher NADIR scores were strongly associated with an early favorable PSA response (odds ratio per 10% increase, 1.74; 95% CI 1.36-2.23; p < 0.001). CRPC-free survival differed significantly across NADIR-defined tertiles, whereas OS did not differ significantly.
conclusionsIn this real-world cohort, the NADIR model retained acceptable predictive performance, suggesting applicability in routine clinical practice and potential utility in individualized pretreatment clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.